Strategic report seeks drug IP reforms in Australia
This article was originally published in SRA
An Australian government-backed report has called for the country to harmonize its intellectual property system with international standards by extending the term of pharmaceutical data exclusivity1,2.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.